4 ms·
Blood Cancer biotech Geron down $1.7B in value, lays off a third of staff
- randycupertino 11mo agoYet another biotech with promising cancer therapies but struggled with clinical and regulatory operations. Telomerase-based cancer therapy has potential for broad applicability unlike targeted therapies, so their “platform” potential is why Geron attracted so much attention and funding despite execution setbacks.